In consultation: Guidance and quality standards
Showing 21 to 23 of 23
| Title | Consultation | Type | Consultation end date |
|---|---|---|---|
| Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Ianalumab for treating active Sjogren's syndrome ID6634 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249] | Draft guidance | Technology appraisal guidance |